PNC Financial Services Group
ADCT icon

PNC Financial Services Group’s ADC Therapeutics ADCT Stock Holding History

PNC Financial Services Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-250
Closed -$498 – 4887
2024
Q4 		$498 Hold
250
– – ﹤0.01% 4531
2024
Q3 		$788 Hold
250
– – ﹤0.01% 4488
2024
Q2 		$790 Hold
250
– – ﹤0.01% 4472
2024
Q1 		$1.12K Hold
250
– – ﹤0.01% 4342
2023
Q4 		$415 Hold
250
– – ﹤0.01% 4435
2023
Q3 		$224 Buy
+250
New +$333 ﹤0.01% 4526

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PNC Financial Services Group's ADCT Position: Q1 2025 in Review

PNC Financial Services Group sold out of ADC Therapeutics (ADCT) in Q1 2025, closing a stake of 250 shares — an estimated $498 sold.

PNC Financial Services Group first reported a position in ADCT in Q3 2023 and held it in 6 quarters. The position peaked at $1.12K in Q1 2024. 82 funds tracked by Wall St. Rank hold ADCT as of Q1 2025.

  • PNC Financial Services Group reported no remaining ADC Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 250 ADC Therapeutics shares in Q1 2025, an estimated $498.
  • PNC Financial Services Group first reported a position in ADC Therapeutics in Q3 2023 and held it in 6 quarters.
  • PNC Financial Services Group's ADC Therapeutics position peaked at $1.12K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2025.

Based on PNC Financial Services Group's 13F filing for Q1 2025, filed 9 May 2025.